<DOC>
	<DOC>NCT00004288</DOC>
	<brief_summary>OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.</brief_summary>
	<brief_title>Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients are treated with daily olsalazine. The dose is increased each week until the protocol dose is reached. Supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue unchanged. Concurrent sulfasalazine is prohibited.</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Olsalazine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Meets modified New York diagnostic criteria Active disease, i.e., morning stiffness for more than 30 minutes Failed or experienced nonlifethreatening reaction to prior sulfasalazine No significant hematologic, hepatic, or renal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>ankylosing spondylitis</keyword>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>rare disease</keyword>
</DOC>